Clinic Locations:
University Medical Center New Orleans
Cancer Center
2000 Canal Street
New Orleans, LA 70112
504.702.5700 (Scheduling line)
504.702.3311 (Cancer Center patient access representative)
Bio
Dr. Omeed Moaven, MD, is a board-certified surgical oncologist and an Associate Professor
of Surgery and Interdisciplinary Oncology at LSU Health New Orleans School of Medicine
and the LSU LCMC Health Cancer Center. He completed his general surgery residency
at Massachusetts General Hospital and the University of Alabama at Birmingham. He
has also completed postdoctoral surgical oncology research fellowships at Massachusetts
General Hospital and a complex general surgical oncology clinical fellowship at Wake
Forest University.
Clinically, Dr. Moaven specializes in hepatopancreatobiliary (HPB) and gastrointestinal
(GI) malignancies—particularly pancreatic cancer, cholangiocarcinoma, hepatocellular
carcinoma, colorectal liver metastases, and peritoneal surface malignancies. He has
interests in program development and has established the EMPOWER Program (Evaluation,
Multimodality Prehabilitation, and Oncology Support: A Well‑being Enhancement Resource)
at UMC, which is a multidisciplinary prehabilitation initiative aimed at improving
physical, nutritional, and psychosocial resiliency in patients undergoing neoadjuvant
therapy to optimize surgical outcomes. He has also established the hepatic arterial
infusion pump (HAIP) program at UMC. In addition, he has established a new cancer
biobank for the LSU Cancer Center biobank and serves as the Cancer Center Biobank
and the biorepository core director.
He is an active clinical trialist and serves as the site PI of several clinical trials
and an investigator initiated clinical trial studying the established prehabilitation
program. Dr. Moaven also leads a translational research program, and his lab investigates
developing effective immuno-oncology approaches in the treatment of pancreatic cancer.
Follow Dr. Moaven on Twitter. 
Education
Medical School:
Doctor of Medicine, 2000-2007
Mashhad University of Medical Sciences
Mashhad, Iran
Residency:
General Surgery Internship & Residency, 2012-2014
Massachusetts General Hospital
Boston, MA
General Surgery Residency, 2015-2018
University of Alabama, Birmingham
Birmingham, AL
Post-Doctoral Fellowship:
Hodin Lab - Dept. of Surgery, 2011-2012
Massachusetts General Hospital/Harvard Medical School
Boston, MA
Tanabe Lab - Division of Surgical Oncology, Department of Surgery, 2014-2015
Massachusetts General Hospital, Harvard Medical School
Boston, MA
Clinical Fellowship:
Complex General Surgical Oncology Fellowship, 2018-2020
Wake Forest University
Winston-Salem, NC
Hospital Affiliations
- UMC New Orleans
- LSU LCMC Health Cancer Center
Clinical Interests
- Pancreas Cancer
- Pancreatic cysts
- Colorectal liver metastasis
- Hepatic Arterial infusion Pump
- Liver cancer
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Peritoneal surface malignancies
- HIPEC
- Gastric cancer
- Colorectal cancer
- Small intestinal cancers
- Neuroendocrine tumors
- Gastrointestinal Stromal Tumors (GIST)
- Retroperitoneal Sarcoma
- Benign pancreas
- Hepatobiliary disease
Research Interests
Dr. Moaven leads a translational research program centered on oncolytic virotherapy
for pancreatic cancer, aiming to turn pancreatic cancer into an immunologically “hot”
tumor, converting immunologically inert pancreatic tumors into ones capable of mounting
a robust immune response. His lab has bioengineered novel viruses designed to remodel
the tumor microenvironment and enhance the effectiveness of immunotherapies. They
evaluate these virotherapies in combination with standard systemic treatments using
in vitro, ex vivo, and in vivo models to measure tumor cytotoxicity and immune modulation.
His lab also investigates immune landscape of pancreatic cancer tumor microenvironment.
He is also the chair of HPB/GI oncology disease group of LSU LCMC Cancer Center, site
PI of Alliance for Clinical Trials in Oncology and site PI of multiple national clinical
trials and the PI of an investigator-initiated trial prospectively investigating a
prehabilitation program for patients with GI malignancy who undergo neoadjuvant treatment.
He also mentors students and residents in clinical outcomes research efforts focused
on GI malignancies.
Awards and Honors
- Norma Lee and Morton Funger Clinician Career Development Award in Pancreatic Cancer Research, Mayo Clinic (2021)